ima203
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03686124)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06946225 | Phase 1 | Jul 25, 2025 | immatics Biotechnologies GmbH, Moderna Therapeutics |
| NCT06743126 | Phase 3 | Dec 31, 2024 | immatics Biotechnologies GmbH |
| NCT03686124 | Phase 1 | Mar 31, 2019 | immatics Biotechnologies GmbH, University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| immatics Biotechnologies GmbH | For profit | 3 | 3 | 2 | 2019 |
| Moderna Therapeutics | For profit | 1 | 0 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1